News
NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...
Treatment Arms: Patients in the active treatment arm will receive two 70mg loading doses (Day 1 and Week 8) followed by two 45mg maintenance doses (Week 24 and Week 40). All patients will continue to ...
16h
Macon Telegraph on MSNMeet the pastor helping to bridge gaps between Macon students, schoolsWith the new school year underway, the Bibb County School District is turning to a familiar face to tackle a persistent ...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today ...
Biogen Inc. Quarterly stock financials by MarketWatch. View the latest BIIB financial statements, income statements and financial ratios.
6h
Zacks Investment Research on MSNDNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26Denali Therapeutics (DNLI) reported a second-quarter 2025 loss of 72 cents per share, narrower than the Zacks Consensus ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...
8h
GlobalData on MSNFirst patient dosed in Phase III trial of zorevunersen for Dravet syndromeThe study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.
Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...
Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results